Further, our finding that CTLA-4 mAb treatment reduced tumor infiltrating Tregs by roughly 50% suggests that Treg depletion may account for some of the immune stimulatory effects observed with CTLA-4 mAb treatment [19, 20]. This evidence concerns the gene CTLA4 and neoplasm.